首頁 > 市場調查報告書 > 製藥

DDS

市場調查報告書

商品編碼

1267725

超級崩解劑全球市場研究報告-2023-2030 年行業分析、規模、份額、增長、趨勢和預測

Global Superdisintegrants Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年04月01日 | 出版商:

Value Market Research | 英文 133 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

超級崩解劑是一種賦形劑，一種添加的惰性物質，有助於藥物的製造、加工和給藥。超級崩解劑用於改善片劑和膠囊在胃腸道中的崩解，這是藥物被吸收並有效分佈到全身所必需的。超級崩解劑在水分存在下會迅速膨脹和分解，從而為水分進入片劑和膠囊並迅速崩解創造途徑。這提高了藥物的生物利用度和功效，因為它被更快、更有效地吸收了。常用的超級崩解劑包括交聯羧甲基纖維素、羥基乙酸澱粉鈉和交聯羧甲基纖維素鈉。這些賦形劑通常與其他賦形劑（如粘合劑和潤滑劑）結合形成完整的片劑或膠囊劑。

市場動態

ODT 是一種快速崩解的片劑，無需水即可在口中溶解。它在老年人和兒童等傳統藥片吞嚥困難的患者中越來越受歡迎。超級崩解劑是ODT的主要成分，隨著對該產品的需求增加，對超級崩解劑的需求也在增加。受社會老齡化、慢性病流行、新興國家醫療保健服務加強等因素影響，全球醫藥行業有望呈現高增長態勢。超級分散劑是許多藥物配方中的重要成分，隨著藥物需求的增加，對超級分散劑的需求也在增加。患者依從性是患者按規定服藥的意願和能力。超降解劑可以提高藥物給藥和吸收的便利性，特別是對於吞嚥片劑和膠囊有困難的患者。隨著醫療保健提供者和製藥公司關注患者的依從性，預計對超降解劑的需求將會增加。仿製藥的興起也推動了對超級分散劑的需求。許多仿製藥製造商正在嘗試開發可與原研品牌相媲美的製劑，而超級崩解劑可用於提高仿製藥產品的性能。超級集成商領域的研究和開發仍在繼續，正在開發更新、更有效的產品。這就是為什麼製藥行業越來越多地採用這些產品，尤其是用於 ODT 和其他快速崩解製劑。

這份研究報告解釋了波特的五力模型、市場吸引力分析和價值鏈分析。這些工具可幫助您清楚地了解您的行業結構並評估您在全球範圍內的競爭吸引力。此外，這些工具還提供了對全球超分散劑市場各個部分的全面評估。超分散劑行業的發展和趨勢為這項研究提供了一種整體方法。

市場細分

本部分提供有關國家/地區級別細分的詳細數據，以幫助戰略制定者確定每種產品/服務的目標受眾和未來商機。.

按類型

天生的超級整合者
合成表面活性劑
其他超級崩解劑

按處方

平板設備
膠囊

按治療領域

消化系統疾病
神經系統疾病
腫瘤學
感染
心血管疾病
血液病
炎症性疾病

區域分析

本節對北美、歐洲、亞太地區、拉丁美洲、中東和非洲超級崩解劑市場當前和未來的需求進行了區域展望。此外，它還側重於所有主要地區每個單獨應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的綜合概況和全球競爭格局的詳細視圖。超級崩解劑市場的主要參與者是 BASF SE、Ashland Global Holding Inc.、DowDuPont、Roquette Freres、DFE Pharma、JRS Pharma、Asahi Kasei Corporation、Merck KGaA、Corel Pharma Chem、Avantor Performance Materials。本節包括對競爭格局的全面了解，包括各種戰略發展，例如主要併購、未來能力、合作夥伴關係、財務概覽、合作、新產品開發和新產品發布。

如果您有任何定制要求，請寫信給我們。我們的研究團隊可以根據您的需要提供定制報告。

內容

第一章前言

報告內容
- 目的
- 目標受眾
- USP（獨特的銷售建議）及其提供的內容
調查範圍
調查方法
- 市場調研流程
- 市場研究方法

第 2 章執行摘要

市場亮點
全球市場概況

第 3 章超級崩解劑 - 行業分析

簡介 - 市場動態
市場驅動力
市場製約因素
機會
行業趨勢
波特的五力分析
市場吸引力分析
- 按類型進行市場吸引力分析
- 按配方進行市場吸引力分析
- 按治療領域進行市場吸引力分析
- 市場吸引力分析：按地區

第四章價值鏈分析

價值鏈分析
原材料分析
- 原材料清單
- 原材料製造商列表
- 主要原材料價格走勢
潛在買家名單
營銷渠道
- 直接營銷
- 間接營銷
- 市場發展趨勢

第 5 章超級崩解劑的全球市場分析：按類型

按類型概述
過去和未來的數據
按類型分析
天生的超級整合者
合成表面活性劑（超級崩解劑
其他超級崩解劑

第 6 章超級崩解劑的全球市場分析：按配方分類

劑型概述
過去和未來的數據
按劑型分析
平板設備
膠囊

第 7 章超級崩解劑的全球市場分析：按治療領域分類

按治療領域概述
過去和未來的數據
按治療領域分析
消化系統疾病
神經系統疾病
腫瘤學
感染
心血管疾病
血液病
炎症性疾病

第 8 章超級崩解劑的全球市場分析：按地區

區域展望
介紹
北美銷售分析
- 概覽、銷售業績和預測分析
- 北美各部門的銷售分析
- 北美銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、銷售業績和預測分析
- 按細分市場進行的歐洲銷售分析
- 按國家/地區劃分的歐洲銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 意大利銷售分析
- 俄羅斯銷售分析
- 其他歐洲銷售分析
亞太地區銷售分析
- 概覽、銷售業績和預測分析
- 亞太地區各部門的銷售分析
- 亞太國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本的銷售分析
- 韓國銷售分析
- 澳大利亞銷售分析
- 其他亞太地區銷售分析
拉丁美洲銷售分析
- 概覽、銷售業績和預測分析
- 拉丁美洲各部門的銷售分析
- 拉丁美洲國家/地區的銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利的銷售分析
- 其他拉丁美洲銷售分析
中東和非洲銷售分析
- 概覽、銷售業績和預測分析
- 中東和非洲各細分市場的銷售額分析
- 中東和非洲國家/地區的銷售分析
- 沙特阿拉伯銷售分析
- 阿聯酋銷售分析
- 以色列銷售分析
- 南非銷售分析
- 其他中東和非洲銷售分析

第 9 章：超分散劑公司的競爭形勢

超級崩解劑市場競爭激烈
夥伴關係/協作/協議
併購
新產品發布
其他擴展

第十章公司簡介

公司股票分析
市場集中度
巴斯夫歐洲公司
- 公司概況
- 企業收入
- 產品介紹
- 近期趨勢
亞甚蘭全球控股公司
- 公司概況
- 企業收入
- 產品介紹
- 近期趨勢
陶氏杜邦公司
- 公司概況
- 企業收入
- 產品介紹
- 近期趨勢
Roquette Freres
- 公司概況
- 企業收入
- 產品介紹
- 近期趨勢
DFE 製藥公司
- 公司概況
- 企業收入
- 產品介紹
- 近期趨勢
JRS 製藥
- 公司概況
- 企業收入
- 產品介紹
- 近期趨勢
旭化成公司
- 公司概況
- 企業收入
- 產品介紹
- 近期趨勢
默克公司
- 公司概況
- 企業收入
- 產品介紹
- 近期趨勢
Corel 製藥化學
- 公司概況
- 企業收入
- 產品介紹
- 近期趨勢
Ava□□ntor 高性能材料
- 公司概況
- 企業收入
- 產品介紹
- 近期趨勢

注意：在公司簡介、財務細節、近期發展等方面，基於可用信息，私人控股公司可能不包括在內。

簡介目錄圖表

Product Code: VMR112110821

The global demand for Superdisintegrants Market is presumed to reach the market size of nearly USD XX MN by 2030 from USD XX MN in 2022 with a CAGR of XX% under the study period 2023 - 2030.

Superdisintegrants are a type of excipient, which are inactive substances that are added to medications to aid in their manufacture, processing, and administration. Superdisintegrants are used to improve the disintegration of tablets and capsules in the gastrointestinal tract, which is necessary for the medication to be absorbed and effectively distributed throughout the body. Superdisintegrants work by rapidly swelling and breaking apart in the presence of moisture, which helps to create channels for water to enter the tablet or capsule, leading to its rapid disintegration. This improves the bioavailability and efficacy of the medication, as it allows for more rapid and efficient absorption. Commonly used superdisintegrants include cross-linked carboxymethyl cellulose, sodium starch glycolate, and croscarmellose sodium. These excipients are often combined with other excipients, such as binders and lubricants, to form a complete tablet or capsule formulation.

Market Dynamics

ODTs are rapidly disintegrating tablets that dissolve in the mouth without the need for water. They are increasingly popular for patients who have difficulty swallowing conventional tablets, such as the elderly and children. Superdisintegrants are a key ingredient in ODTs, and as demand for these products increases, so too does the demand for superdisintegrants. The global pharmaceutical industry is expected to showcase high growth due to factors such as aging population growth, the prevalence of chronic diseases, and the increasing availability of healthcare services in emerging markets. Superdisintegrants are a critical ingredient in many pharmaceutical formulations, and as the demand for medications increases, so does the demand for superdisintegrants. Patient compliance refers to a patient's willingness and ability to take medications as prescribed. Superdisintegrants can improve the ease of administration and absorption of medications, particularly for patients who have difficulty swallowing tablets or capsules. As healthcare providers and pharmaceutical companies focus more on patient compliance, the demand for superdisintegrants is expected to increase. The increasing availability of generic medications is driving the demand for superdisintegrants. Many generic manufacturers are looking to develop formulations that are equivalent to the brand-name product, and superdisintegrants can be used to improve the performance of the generic product. There has been ongoing research and development in the area of superdisintegrants, resulting in the development of newer and more effective products. This has led to increased adoption of these products in the pharmaceutical industry, particularly for use in ODTs and other rapidly disintegrating formulations.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of superdisintegrants. The growth and trends of superdisintegrants industry provide a holistic approach to this study.

Market Segmentation

This section of the superdisintegrants market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Natural Superdisintegrants
Synthetic Superdisintegrants
Other Superdisintegrants

By Formulation

Tablets
Capsules

By Therapeutic Area

Gastrointestinal Diseases
Neurological Diseases
Oncology
Infectious Diseases
Cardiovascular Diseases
Hematological Diseases
Inflmmatory Diseases

Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the Superdisintegrants market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the superdisintegrants market include BASF SE, Ashland Global Holding Inc., DowDuPont, Roquette Freres, DFE Pharma, JRS Pharma, Asahi Kasei Corporation, Merck KGaA, Corel Pharma Chem, Avantor Performance Materials. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . SUPERDISINTEGRANTS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Formulation
- 3.7.3 Market Attractiveness Analysis By Therapeutic Area
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL SUPERDISINTEGRANTS MARKET ANALYSIS BY TYPE

5.1 Overview by Type
5.2 Historical and Forecast Data
5.3 Analysis by Type
5.4 Natural Superdisintegrants Historic and Forecast Sales by Regions
5.5 Synthetic Superdisintegrants Historic and Forecast Sales by Regions
5.6 Other Superdisintegrants Historic and Forecast Sales by Regions

6 . GLOBAL SUPERDISINTEGRANTS MARKET ANALYSIS BY FORMULATION

6.1 Overview by Formulation
6.2 Historical and Forecast Data
6.3 Analysis by Formulation
6.4 Tablets Historic and Forecast Sales by Regions
6.5 Capsules Historic and Forecast Sales by Regions

7 . GLOBAL SUPERDISINTEGRANTS MARKET ANALYSIS BY THERAPEUTIC AREA

7.1 Overview by Therapeutic Area
7.2 Historical and Forecast Data
7.3 Analysis by Therapeutic Area
7.4 Gastrointestinal Diseases Historic and Forecast Sales by Regions
7.5 Neurological Diseases Historic and Forecast Sales by Regions
7.6 Oncology Historic and Forecast Sales by Regions
7.7 Infectious Diseases Historic and Forecast Sales by Regions
7.8 Cardiovascular Diseases Historic and Forecast Sales by Regions
7.9 Hematological Diseases Historic and Forecast Sales by Regions
7.10. Inflmmatory Diseases Historic and Forecast Sales by Regions

8 . GLOBAL SUPERDISINTEGRANTS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE SUPERDISINTEGRANTS COMPANIES

9.1. Superdisintegrants Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF SUPERDISINTEGRANTS INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. BASF SE
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. Ashland Global Holding Inc.
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. DowDuPont
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Roquette Freres
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. DFE Pharma
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. JRS Pharma
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. Asahi Kasei Corporation
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Merck KGaA
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. Corel Pharma Chem
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments
10.12. Avantor Performance Materials
- 10.12.1. Company Overview
- 10.12.2. Company Revenue
- 10.12.3. Products
- 10.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

簡介目錄圖表